Carboplatin is one of the most broadly used anticancer agents. The exclusivity for Bristol-Myers Squibb’s Paraplatin expired in 2004, after which generic versions of the product were approved. Spectrum anticipates receiving final FDA approval for its product by mid-year and, upon launch, the product will be Spectrum’s first injectable anticancer on the market.
“We are delighted to have entered into this agreement with Cura Pharmaceuticals to market and distribute Spectrum’s first anticancer injectable product,” stated Dr Rajesh Shrotriya, chairman, chief executive officer and president of Spectrum.
“We believe that the Cura team has the necessary background, experience, resources and commitment in the anticancer injectable field to be able to obtain significant sales for Spectrum’s ‘ready to use’ carboplatin product.”